The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Takeda’s (TAK +0.4%)
Alunbrig (brigatinib) as monotherapy for the treatment of adult
patients with anaplastic lymphoma kinase-positive (ALK+) advanced
non-small cell lung cancer (NSCLC) who have not received prior treatment
with an ALK inhibitor.
A final decision from the European Commission usually takes ~60 days.
https://seekingalpha.com/news/3547494-european-advisory-group-backs-takedas-brigatinib-for-type-of-lung-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.